☰

Rahul R. Nahar, Ph.D. - Publications

Affiliations: 
2010 Biochemistry and Molecular Biology University of Southern California, Los Angeles, CA, United States 
Area:
Molecular Biology, Genetics, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Lai GGY, Lim TH, Lim J, Liew PJR, Kwang XL, Nahar R, Aung ZW, Takano A, Lee YY, Lau DPX, Tan GS, Tan SH, Tan WL, Ang MK, Toh CK, et al. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800177. PMID 30676858 DOI: 10.1200/Jco.18.00177  0.391
2018 Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, Duan K, Ang N, Poidinger M, Lee YY, Larbi A, et al. Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. PMID 29769722 DOI: 10.1038/S41586-018-0130-2  0.305
2018 Nahar R, Zhai W, Zhang T, Takano A, Khng AJ, Lee YY, Liu X, Lim CH, Koh TPT, Aung ZW, Lim TKH, Veeravalli L, Yuan J, Teo ASM, Chan CX, et al. Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. Nature Communications. 9: 216. PMID 29335443 DOI: 10.1038/S41467-017-02584-Z  0.322
2018 Kwang L, Lau D, Liew A, Ju Y, Lim E, Lai G, Nahar R, Teng Y, Chua K, Alvarez J, Lim M, Leong H, Chong F, Toh D, Quah H, et al. P2.13-21 MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLCX. Journal of Thoracic Oncology. 13: S806. DOI: 10.1016/J.Jtho.2018.08.1416  0.317
2015 Geng H, Hurtz C, Lenz KB, Chen Z, Baumjohann D, Thompson S, Goloviznina NA, Chen WY, Huan J, LaTocha D, Ballabio E, Xiao G, Lee JW, Deucher A, Qi Z, ... ... Nahar R, et al. Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer Cell. 27: 409-25. PMID 25759025 DOI: 10.1016/J.Ccell.2015.02.003  0.731
2015 Nahar R, Zhai W, Takano A, Khng AJ, Liu X, Lim CH, Teo ASM, Chan CX, Gogna A, Lim K, Koh T, Poh HM, Lee YY, Chen LH, Zhang T, et al. Abstract A1-25: Intratumor heterogeneity in never-smoker Asian EGFR mutant lung adenocarcinoma Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-25  0.32
2014 Geng H, Hurtz C, Baumjohann D, Chen Z, Chen W, Ballabio E, Xiao G, Lee J, Deucher A, Qi Z, Huang C, Nahar R, Kweon S, Shojaee S, Chan LN, et al. Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia Blood. 124: 284-284. DOI: 10.1182/Blood.V124.21.284.284  0.776
2013 Geng H, Hurtz C, Chen Z, Chen W, Ballabio E, Xiao G, Kweon S, Nahar R, Sojaee S, Chan LN, Masouleh BK, Sykes DB, Melnick A, Roeder R, Milne T, et al. Targeting Pre-B Cell Receptor and BCL6 In TCF3-PBX1 B-Lineage Acute Lymphoblastic Leukemia Blood. 122: 349-349. DOI: 10.1182/Blood.V122.21.349.349  0.723
2011 Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, Ye BH, Melnick A, Müschen M. Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 118: 4174-8. PMID 21856866 DOI: 10.1182/Blood-2011-01-331181  0.73
2011 Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon SM, Nahar R, Braig M, Park E, Kim YM, Hofmann WK, Herzog S, Jumaa H, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 473: 384-8. PMID 21593872 DOI: 10.1038/Nature09883  0.689
2011 Nahar R, Ramezani-Rad P, Dovat S, Buchner M, Graeber TG, Muschen M. Mechanisms of Ikaros-Mediated Tumor Suppression Blood. 118: 408-408. DOI: 10.1182/Blood.V118.21.408.408  0.724
2010 Duy C, Yu JJ, Nahar R, Swaminathan S, Kweon SM, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L, Schuh W, Jäck HM, Hurtz C, Ramezani-Rad P, Herzog S, et al. BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of Experimental Medicine. 207: 1209-21. PMID 20498019 DOI: 10.1084/Jem.20091299  0.757
2010 Ng C, Nahar R, Elliott E, Lowell CA, Muschen M. SYK Is a Tumor Suppressor In Pre-B Cell Acute Lymphoblastic Leukemia and Not a Therapeutic Target Blood. 116: 4199-4199. DOI: 10.1182/Blood.V116.21.4199.4199  0.757
2010 Nahar R, Trageser D, Klemm L, Duy C, Hofmann W, Park E, Kim Y, Heisterkamp N, Jumaa H, Muschen M. Pre-B Cell Receptor Signaling Distinguishes E2A-PBX1 From Other Subtypes of Acute Lymphoblastic Leukemia Blood. 116: 274-274. DOI: 10.1182/Blood.V116.21.274.274  0.748
2010 Duy C, Nowak D, Klemm L, Nahar R, Ng C, Elliott E, Hofmann W, Heisterkamp N, Lowell CA, Koeffler P, Muschen M. Mechanisms of Pre-B Cell Receptor-Inactivation In Acute Lymphoblastic Leukemia Blood. 116: 147-147. DOI: 10.1182/Blood.V116.21.147.147  0.761
2010 Nahar R, Ramezani-Rad P, Duy C, Dovat S, Ye BH, Melnick AM, Muschen M. IKAROS and BCL6 Limit Pre-B Cell Expansion and Prevent Leukemogenesis Downstream of the Pre-B Cell Receptor Blood. 116: 146-146. DOI: 10.1182/Blood.V116.21.146.146  0.762
2009 Nahar R, Müschen M. Pre-B cell receptor signaling in acute lymphoblastic leukemia. Cell Cycle (Georgetown, Tex.). 8: 3874-7. PMID 19901533 DOI: 10.4161/Cc.8.23.10035  0.736
2009 Trageser D, Iacobucci I, Nahar R, Duy C, von Levetzow G, Klemm L, Park E, Schuh W, Gruber T, Herzog S, Kim YM, Hofmann WK, Li A, Storlazzi CT, Jäck HM, et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. The Journal of Experimental Medicine. 206: 1739-53. PMID 19620627 DOI: 10.1084/Jem.20090004  0.676
2009 Duy C, Yu JJ, Swaminathan S, Nahar RR, Kweon S, Polo JM, Valls E, Klemm L, Cerchietti L, Levetzow Gv, Herzog S, Jumaa H, Alborán IMd, Melnick A, Ye BH, et al. BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire. Blood. 114: 91-91. DOI: 10.1182/Blood.V114.22.91.91  0.763
2009 Duy C, Cerchietti L, Yu JJ, Ci W, Swaminathan S, Nahar RR, Kweon S, Klemm L, Ye BH, Melnick A, Müschen M. BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 765-765. DOI: 10.1182/Blood.V114.22.765.765  0.725
2009 Duy C, Sprangers M, Klemm L, Nahar RR, Nowak D, Martinelli G, Hofmann W, Koeffler PH, Jumaa H, Müschen M. Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph+ Acute Lymphoblastic Leukemia. Blood. 114: 579-579. DOI: 10.1182/Blood.V114.22.579.579  0.712
2009 Nowak D, Kawamata N, Niebuhr B, Nowak V, Mossner M, Nahar RR, Thoennissen NH, Iwanski GB, Stocking C, Dugas M, Hofmann WK, Müschen M, Koeffler PH. The Pax5 Fusion Product Pax5-C20orf112 Causes Downregulation of Pre-B Cell Receptor Genes and Induces Differential Proliferation Patterns in B-Lymphoblastic Cell Lines. Blood. 114: 1284-1284. DOI: 10.1182/Blood.V114.22.1284.1284  0.724
2008 Duy C, Klemm L, Nahar R, Essen Pv, Sprangers M, Kim Y, Park E, Martinelli G, Heisterkamp N, Hofmann W, Jumaa H, Muschen M. Aberrant Splicing of the SLP65 SH2 Domain Enables Pre-B Cell Transformation and Compromises the Leukemia-Suppressive Function of the Pre-B Cell Receptor Blood. 112: 294-294. DOI: 10.1182/Blood.V112.11.294.294  0.746
Show low-probability matches.